



28th September, 2023

BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai- 400 001
BSE scrip code: 543635

National Stock Exchange of India Limited
Exchange Plaza, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051
NSE symbol: PPLPHARMA

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Successful closure of US FDA Inspection at Piramal Pharma's manufacturing facility located at Bethlehem, USA

Dear Sir / Madam,

This is to inform you that the US FDA conducted a Good Manufacturing Practices (GMP) Inspection of Piramal Pharma Limited's Bethlehem facility from 18th September 2023 to 27th September 2023.

On conclusion of the inspection, a Form-483 was issued with 2 observations. Both observations relate to system improvement only, and none are related to data integrity. The Company is preparing a detailed response to said observations, which will be submitted to the US FDA within stipulated timelines.

The Company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all observations.

This is for your information and records.

Thanking you,

Yours truly,
For **Piramal Pharma Limited**

Tanya Sanish
Company Secretary